Get the Stockscreener App
135.43
0.11%
0.15
Neurocrine Biosciences Inc stock is traded at $135.43, with a volume of 547.97K.
It is up +0.11% in the last 24 hours and up +2.02% over the past month.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$135.28
Open:
$135.97
24h Volume:
547.97K
Relative Volume:
0.59
Market Cap:
$13.43B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
45.91
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
+1.90%
1M Performance:
+2.02%
6M Performance:
+12.21%
1Y Performance:
-11.23%
1-Day Range:
$134.31
$137.03
1-Week Range:
$131.91
$137.03
52-Week Range:
$84.23
$154.87
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
135.43 | 13.21B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Singer Carnie Wilson and Dr. Greg Mattingly discuss tardive dyskinesia on Your Day - WKEF
Will Neurocrine Biosciences Inc. stock go up soonTrend Reversal & AI Enhanced Execution Alerts - Newser
Published on: 2025-08-20 04:48:02 - classian.co.kr
Will Neurocrine Biosciences Inc. price bounce be sustainableEarnings Overview Report & Precise Trade Entry Recommendations - Newser
Long term hold vs stop loss in Neurocrine Biosciences Inc.Weekly Trading Summary & Daily Profit Focused Stock Screening - Newser
How to integrate Neurocrine Biosciences Inc. into portfolio analysis toolsPortfolio Return Report & Precise Trade Entry Recommendations - Newser
Using portfolio simulators with Neurocrine Biosciences Inc. included2025 Performance Recap & Verified Trade Idea Suggestions - Newser
Does Neurocrine Biosciences Inc. fit your quant trading modelJuly 2025 Action & Community Consensus Picks - Newser
Real time scanner hits for Neurocrine Biosciences Inc. explainedRate Cut & Daily Profit Maximizing Trade Tips - Newser
Relative strength of Neurocrine Biosciences Inc. in sector analysisPortfolio Performance Report & Reliable Intraday Trade Plans - Newser
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2025 Earnings Call Transcript - MSN
Order flow analysis tools used on Neurocrine Biosciences Inc.2025 Buyback Activity & Daily Profit Focused Screening - Newser
Ranking Neurocrine Biosciences Inc. among high performing stocks via toolsWeekly Gains Summary & Breakout Confirmation Trade Signals - Newser
Will Neurocrine Biosciences Inc. stock recover after recent dropJuly 2025 PostEarnings & Weekly Chart Analysis and Guides - Newser
Is Neurocrine Biosciences Inc. stock reversal real or fakeQuarterly Earnings Report & Weekly Market Pulse Updates - Newser
Top chart patterns to watch in Neurocrine Biosciences Inc.Dollar Strength & AI Enhanced Trading Alerts - Newser
What’s the recovery path for long term holders of Neurocrine Biosciences Inc.2025 Historical Comparison & Risk Adjusted Buy and Sell Alerts - Newser
Published on: 2025-08-16 23:41:15 - Newser
Understanding Neurocrine Biosciences Inc.’s price movementTrade Performance Summary & Fast Exit and Entry Strategy Plans - Newser
Truist Securities Initiates Coverage of Neurocrine Biosciences (NBIX) with Buy Recommendation - MSN
Visual analytics tools that track Neurocrine Biosciences Inc. performancePortfolio Value Summary & Low Risk Entry Point Tips - Newser
Reversal Traders Monitor Neurocrine Biosciences Inc. for EntryJuly 2025 Institutional & Weekly Sector Rotation Insights - metal.it
Trendlines Converge — Decision Point for Neurocrine Biosciences Inc.July 2025 Recap & Stock Market Timing Techniques - beatles.ru
Real time social sentiment graph for Neurocrine Biosciences Inc.2025 Big Picture & Technical Confirmation Alerts - Newser
Earnings visualization tools for Neurocrine Biosciences Inc.2025 Price Targets & Precise Trade Entry Recommendations - Newser
Published on: 2025-08-15 16:55:58 - Newser
PNC Financial Services Group Inc. Cuts Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World
What Technical Tools Say About Neurocrine Biosciences Inc. RecoveryJuly 2025 Macro Moves & Weekly High Return Stock Opportunities - newsimpact.co.kr
Neurocrine at Canaccord Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
US Bancorp DE Has $412,000 Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World
Stronger-Than-Expected Q2 Results Could Be a Game Changer for Neurocrine Biosciences (NBIX) - simplywall.st
Neurocrine Biosciences Director Gorman Buys, Sells 106,322 Shares on 8/7/2025 - AInvest
Neurological Disorder Drugs Market Set to Witness Significant - openPR.com
Will Neurocrine Biosciences Inc. bounce back from current supportWatchlist Summary for Active Day Traders - Newser
What’s next for Neurocrine Biosciences Inc. stock priceFree Daily Growth Stock Pick Reports - Newser
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025 - GlobeNewswire Inc.
Neurocrine Biosciences shares rise 3.11% after-hours following Nxera Pharma's obesity pipeline progress. - AInvest
This Neurocrine Biosciences Insider Reduced Their Stake By 28% - 富途牛牛
Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference - Yahoo Finance
Neurocrine Biosciences shares fall 1.10% intraday as Nxera Pharma launches obesity drug pipeline. - AInvest
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Tardive Dyskinesia Drugs Market Exclusive Report with Detailed - openPR.com
Neurocrine Biosciences (NASDAQ:NBIX) Upgraded at Wall Street Zen - Defense World
Guggenheim Boosts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $175.00 - MarketBeat
CRENESSITY's Breakout Launch Might Change the Case for Investing in Neurocrine Biosciences (NBIX) - simplywall.st
William Blair Analysts Increase Earnings Estimates for NBIX - Defense World
What drives Neurocrine Biosciences Inc. stock priceUnlock powerful trading alerts for success - Jammu Links News
Is Neurocrine Biosciences Inc. a growth stock or a value stockTremendous wealth creation - Jammu Links News
Neurocrine Biosciences Inc. Stock Analysis and ForecastRapid portfolio appreciation - Jammu Links News
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $144.00 at Royal Bank Of Canada - MarketBeat
How does Neurocrine Biosciences Inc. generate profit in a changing economyMaximize portfolio value with smart investment plans - Jammu Links News
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neurocrine Biosciences Inc Stock (NBIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GORMAN KEVIN CHARLES | Director |
Aug 07 '25 |
Sale |
126.41 |
106,322 |
13,440,281 |
514,596 |
0.51%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):